Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Blood (2022) 140 (Supplement 1): 3532–3533.

https://doi.org/10.1182/blood-2022-156571

Published: 2022

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

Identification of Genetic Subtypes in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6371–6373.

https://doi.org/10.1182/blood-2022-164610

Published: 2022

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

Mina Dehghani Mohammadabadi, MD, Annette E Hay, Lois E. Shepherd, Michael Crump, MD, Bingshu E. Chen, Tara Baetz, MD

Blood (2018) 132 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2018-99-116316

Published: 2018

Journal Articles

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Shen Li, MD, Annette E Hay, Michael Crump, MD, Peter Anglin, MD FRCPC, MBA, Tara Baetz, Ralph Meyer, MDFRCPC, Armand Keating, MD, Sue Robinson, MD, Matthew Seftel, MRCP, MD MPH, FRCPC, Caterina Stelitano, Marina S Djurfeldt, MSc, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 2015.

https://doi.org/10.1182/blood.V130.Suppl_1.2015.2015

Published: 2017

Journal Articles

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

Kathrin Tyryshkin, PhD, Yi D Li, MD, David Good, MD, Lois E. Shepherd, MD, Tara Baetz, MD FRCPC, Michael J. Rauh, MD PhD, David P. LeBrun, MD

Blood (2016) 128 (22): 3037.

https://doi.org/10.1182/blood.V128.22.3037.3037

Published: 2016

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma

Rashmi S. Goswami, BSc, MD, FRCPC, Levi Waldron, Ph.D., Patricia P Reis, Ph.D., Yali Xuan, Wei Xu, Ph.D., John Kuruvilla, David Good, MD, Denis Bailey, MD, Alanna Church, MD, Tara Baetz, MD, David LeBrun, MD, Raymond Lai, MD, Ph.D., Laurie Sehn, MD, MPH, Pedro Farinha, MD, Randy D. Gascoyne, MD, Michael Crump, MD, FRCPC, Igor Jurisica, Ph.D., Suzanne Kamel-Reid, Ph.D.

Blood (2010) 116 (21): 800.

https://doi.org/10.1182/blood.V116.21.800.800

Published: 2010

Journal Articles

Fibrosis in Nodular Sclerosis Hodgkin Lymphoma Is Predictive of a Residual Mass Following Therapy.

Alanna J Church, MSc, MD, Nasim Shabazi, MD, David LeBrun, MD, FRCPC, Tara Baetz, MD, FRCPC

Blood (2009) 114 (22): 4630.

https://doi.org/10.1182/blood.V114.22.4630.4630

Published: 2009

Journal Articles

Developing a Multidimensional Prognostic Test for Follicular Lymphoma.

Cheryl J. Foster, BSc, Tara Baetz, MD, Roland Somogyi, PhD, Larry D. Greller, PhD, Roger Sidhu, MD, Patricia Farmer, MD, Harriet E. Feilotter, PhD, David P. LeBrun, MD

Blood (2007) 110 (11): 2610.

https://doi.org/10.1182/blood.V110.11.2610.2610

Published: 2007

Journal Articles

Identification of Combined Clinical and Biomarker Prognostic Factors in Follicular Lymphoma.

Cheryl J. Foster, BSc, Patricia L. Farmer, MD, Tara Baetz, MD, Julia Brettschneider, PhD, Harriet E. Feilotter, PhD, David P. LeBrun, MD

Blood (2006) 108 (11): 4603.

https://doi.org/10.1182/blood.V108.11.4603.4603

Published: 2006

NARROW

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Identification of Genetic Subtypes in Follicular Lymphoma

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma

Fibrosis in Nodular Sclerosis Hodgkin Lymphoma Is Predictive of a Residual Mass Following Therapy.

Developing a Multidimensional Prognostic Test for Follicular Lymphoma.

Identification of Combined Clinical and Biomarker Prognostic Factors in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only